LXRX
Lexicon Pharmaceuticals, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
5.37
P/S
13.53
EV/EBITDA
-16.44
DCF Value
$-10.82
FCF Yield
-10.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
98.9%
Operating Margin
-98.2%
Net Margin
-101.1%
ROE
-41.9%
ROA
-27.2%
ROIC
-28.7%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $5.5M | $-15.5M | $-0.04 |
| FY 2025 | $49.8M | $-50.3M | $-0.14 |
| Q3 2025 | $14.2M | $-12.8M | $-0.04 |
| Q2 2025 | $28.9M | $3.3M | $0.01 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.95
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.